Imerslund Grasbeck syndrome
Imerslund–Gräsbeck syndrome (IGS) is a rare autosomal recessive cause of childhood vitamin B12 deficiency characterized by selective intestinal malabsorption of cobalamin, typically presenting with megaloblastic anemia and mild, non‑progressive low–molecular‑weight proteinuria, due to mutations in the CUBN or AMN genes encoding the ileal “cubam” receptor. With lifelong parenteral vitamin B12 replacement, hematologic and neurologic outcomes are usually excellent, while the proteinuria persists without leading to renal failure.[1][2][3][4][5]
Overview and definition
Imerslund–Gräsbeck syndrome (also called selective vitamin B12 malabsorption with proteinuria or megaloblastic anemia, Finnish/Norwegian type) is an inherited disorder in which vitamin B12 (cobalamin) cannot be absorbed in the terminal ileum despite normal intrinsic factor production and gastric function. Clinically it is defined by:[3][6][1]
- Early‑onset megaloblastic anemia due to B12 deficiency.
- Low B12 absorption not corrected by intrinsic factor on absorption testing.
- Frequently, mild low–molecular‑weight proteinuria with otherwise normal renal function.[7][1][3]
Epidemiology
The syndrome was first described in families from Finland and Norway, where the prevalence is estimated at roughly 1 in 200,000. It is now reported worldwide, with additional clusters among certain ethnic groups, including North African Jews and families in the Eastern Mediterranean, Middle East, and South Asia. Overall, only a few hundred cases have been documented, and IGS is considered an ultra‑rare cause of B12 deficiency in children.[8][9][5][1][3]
Onset is typically in infancy or early childhood, most often between 4 months and several years of age, not immediately after birth as in some other inherited B12 disorders.[4][1][3]
Genetic basis and pathophysiology
CUBAM receptor complex
Imerslund–Gräsbeck syndrome is caused by biallelic pathogenic variants in genes encoding components of the cubam receptor complex:
Cubilin is a large, peripheral membrane receptor that binds the intrinsic factor–vitamin B12 (IF–B12) complex at the brush border of ileal enterocytes and also acts, together with amnionless, as a multiligand scavenger receptor in proximal renal tubules. Amnionless is a transmembrane protein that anchors cubilin to the cell surface and is essential for trafficking cubilin to the apical membrane in both intestine and kidney.[1][3][10][4]
Mutations in CUBN or AMN disrupt the cubam receptor, leading to:[7][3][4][1]
- Selective intestinal malabsorption of vitamin B12 despite normal intrinsic factor and gastric acid.
- Defective reabsorption of filtered low–molecular‑weight proteins in the proximal tubule, causing mild proteinuria.
NORD and MONDO distinguish:
- IGS type 1: CUBN‑related (“megaloblastic anemia, Finnish type”).[6]
- IGS type 2: AMN‑related (“megaloblastic anemia, Norwegian type”).[7]
Both types share the same core phenotype of juvenile megaloblastic anemia with selective B12 malabsorption and often proteinuria.[3][6][7]
Clinical manifestations
Hematologic and systemic features
The primary feature is megaloblastic anemia due to B12 deficiency, with typical manifestations:[8][4][1][3]
- Failure to thrive and poor weight gain.
- Pallor, fatigue, lethargy.
- Recurrent infections (respiratory or gastrointestinal).
- Laboratory evidence of macrocytosis, hypersegmented neutrophils, and elevated LDH and bilirubin.
GARD and MedlinePlus note that some patients present later with anemia plus mild neurologic symptoms, including hypotonia, paresthesias, gait disturbance, or cognitive/behavioral changes if B12 deficiency is prolonged.[4][6][8]
Renal findings: proteinuria
About half of patients have persistent mild proteinuria, usually discovered incidentally. Key points:[1][3][4][7]
- Proteinuria is typically low–molecular‑weight and albumin‑predominant, reflecting proximal tubular reabsorption failure.[2]
- Detailed nephrology studies in cubilin‑deficient adults showed increased excretion of total protein, albumin, transferrin, immunoglobulin light chains, and microglobulins, but normal glomerular filtration and no progression to renal failure.[2]
- Kidney biopsies, when performed, show subtle mesangial changes but no progressive glomerulopathy.[11][2]
Both Orphanet and NORD emphasize that the proteinuria is non‑progressive and does not generally lead to impaired kidney function. Recognizing this benign proteinuria helps avoid unnecessary renal work‑up or treatment.[2][7][1]
Other features
Additional manifestations reported in Orphanet, OJRD and GARD include:[8][3][1]
- Mild neurologic impairment if deficiency is untreated (hypotonia, developmental delay, neuropathy, ataxia, confusion).
- Occasional urinary tract anomalies (e.g., duplicated ureters, other structural anomalies) in some Norwegian patients, though their pathogenetic link to IGS is uncertain.[1]
With timely parenteral B12 treatment, most neurologic manifestations are preventable or reversible, especially if therapy begins before severe and prolonged deficiency.[5][10][3]
Natural history
Symptoms usually begin in late infancy or early childhood, often with failure to thrive, pallor, and recurrent infections.[3][4][1]
- Without treatment, progressive megaloblastic anemia and neurologic damage can occur.
- Once diagnosed and treated with lifelong parenteral B12, hematologic abnormalities normalize and patients can remain clinically well for decades.[10][5][3][1]
- Proteinuria persists but remains clinically benign.[2][1]
Long‑term follow‑up data, including the 50‑year perspective review by Gräsbeck, confirm that children with IGS who receive adequate parenteral B12 have normal life expectancy and quality of life.[10][3]
Diagnosis
Laboratory findings
Typical lab abnormalities include:[5][4][3][1]
- Macrocytic, megaloblastic anemia (elevated MCV, low Hb).
- Low serum vitamin B12 with normal folate.
- Elevated homocysteine and methylmalonic acid (biochemical evidence of tissue B12 deficiency).
- Normal or mildly elevated LDH, indirect bilirubin.
- Urine protein: persistent mild proteinuria, often with a pattern of low–molecular‑weight proteins and albumin on electrophoresis.[11][2]
Vitamin B12 absorption testing
Classically, diagnosis relied on the Schilling test:[12][13][3][1]
- Oral radiolabeled vitamin B12 shows low urinary excretion, indicating malabsorption.
- Addition of intrinsic factor does not correct the malabsorption (distinguishing IGS from intrinsic‑factor deficiency/pernicious anemia).
Because the Schilling test is now rarely available, alternative approaches (oral B12 loading tests with serum kinetics, fecal recovery studies) or genetic testing are used instead.[3][10]
Importantly, Orphanet notes that B12 deficiency itself can impair enterocyte function, so absorption tests should be repeated after repletion to avoid misinterpreting generalized malabsorption as selective B12 malabsorption.[1][3]
Genetic confirmation
Today, definitive diagnosis is increasingly based on molecular testing:[6][4][3][1]
- Targeted sequencing of CUBN and AMN in patients with compatible phenotype.
- Inclusion of these genes in broader congenital B12 deficiency or megaloblastic anemia panels.
NORD and MONDO describe IGS type 1 (CUBN‑related) and type 2 (AMN‑related) variants, both causing enterocyte cobalamin malabsorption with proteinuria. Identification of the causal variant confirms the diagnosis and allows carrier and prenatal testing in at‑risk families.[4][6][7][10]
Differential diagnosis
Key differentials include other causes of childhood cobalamin deficiency and megaloblastic anemia:
- Nutritional B12 deficiency (maternal veganism, malnutrition): usually associated with low maternal B12 and responds to oral B12; no proteinuria.[10]
- Intrinsic factor deficiency (IFD) / congenital pernicious anemia (GIF mutations): B12 malabsorption that corrects with intrinsic factor on absorption testing; no proteinuria.[10]
- Transcobalamin II deficiency: early‑onset B12 deficiency with failure to thrive and immunologic problems, but no selective ileal defect or proteinuria; symptoms often begin in the neonatal period.[3][10]
- Other malabsorption syndromes (celiac disease, Crohn disease, short‑bowel, pancreatic insufficiency): associated with broad malabsorption of multiple nutrients and gastrointestinal symptoms; absorption tests or endoscopy differentiate them.[3]
- Inborn errors of cobalamin metabolism (e.g., cblC, methylmalonic acidemia with homocystinuria): typically present with neurologic/metabolic crises, elevated homocysteine and methylmalonic acid, but normal B12 absorption and no proteinuria.[10][3]
The combination of selective B12 malabsorption not corrected by intrinsic factor plus benign proteinuria is highly suggestive of IGS.[5][1][3]
Management
Vitamin B12 replacement
Management is straightforward and highly effective: lifelong parenteral vitamin B12.[5][1][3][10]
- Typical regimens (varies by center):
- Intensive loading phase (e.g., 1,000 µg intramuscular cyanocobalamin daily or several times weekly for 1–2 weeks), followed by
- Hematologic response is usually rapid, with reticulocytosis within days and normalization of Hb and MCV over several weeks.[5][3]
- Neurologic symptoms, if present, often improve substantially, particularly if treatment starts early.[4][3][10]
Because the absorption defect is permanent, parenteral therapy is preferred; some centers trial high‑dose oral B12 in selected patients, but guidelines and most reviews still recommend intramuscular therapy as standard.[3][10]
Management of proteinuria and renal follow‑up
No specific renal treatment is needed. Prospective nephrology studies show:[7][2][1]
- Proteinuria is stable or improves slightly with time and B12 therapy.[11][2]
- Overall renal function (GFR) remains normal over long‑term follow‑up.[2][3]
Standard periodic urinalysis and kidney function monitoring is reasonable, but aggressive nephrologic interventions are generally unnecessary.
Monitoring and supportive care
Additional considerations:[10][5][3]
- Regular monitoring of CBC, serum B12, and metabolic markers (homocysteine, methylmalonic acid) to ensure adequacy of replacement.
- Developmental and neurologic surveillance in early childhood.
- Education of families and, eventually, patients about the lifelong need for B12 injections and recognition of relapse symptoms if doses are missed.
Prognosis
With accurate diagnosis and adherence to parenteral B12 therapy, prognosis is excellent:[1][5][3][10]
- Anemia and most systemic/neurologic manifestations are fully reversible.
- Patients can lead normal lives, including normal growth, schooling, and fertility.
- Long‑term kidney function remains intact despite ongoing proteinuria.[2][3]
Severe neurologic sequelae are mainly seen in undiagnosed or late‑treated cases where B12 deficiency persists for prolonged periods in early childhood.[4][3][10]
Genetic counseling
IGS is inherited in an autosomal recessive manner.[6][4][1][3]
- Each child of carrier parents has a 25% risk of being affected, 50% chance of being an asymptomatic carrier, and 25% chance of being unaffected and non‑carrier.
- Once a familial CUBN or AMN variant is identified, carrier testing for at‑risk relatives and prenatal or preimplantation genetic diagnosis can be offered.[6][4][10]
Because some populations (e.g., families from Scandinavia, North Africa, Eastern Mediterranean) have higher reported case numbers, ethnicity and family history can be useful clues prompting targeted genetic evaluation in children with unexplained megaloblastic anemia and proteinuria.[5][3][10]
Key points for medical writers
- Emphasize that Imerslund–Gräsbeck syndrome is a selective B12 malabsorption with benign proteinuria, caused by CUBN/AMN (cubam) mutations, and is fully treatable with lifelong parenteral B12.[4][1][3]
- Highlight its clinical red flags: childhood megaloblastic anemia unresponsive to oral B12, low B12 absorption not corrected by intrinsic factor, plus mild proteinuria with normal renal function.[1][3][5]
- Use trusted sources such as Orphanet (ORPHA:35858), Orphanet Journal of Rare Diseases review (Gräsbeck 2006), MedlinePlus Genetics, NORD/GARD, and key nephrology papers on cubilin‑related proteinuria for referenced content.[8][7][2][4][1][3]
References
- https://www.orpha.net/en/disease/detail/35858
- https://pubmed.ncbi.nlm.nih.gov/12687456/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC1513194/
- https://medlineplus.gov/genetics/condition/imerslund-grasbeck-syndrome/
- https://jlabphy.org/unusual-cause-of-childhood-anemia-imerslund-grasbeck-syndrome/
- https://rarediseases.org/mondo-disease/imerslund-grasbeck-syndrome-type-1/
- https://rarediseases.org/mondo-disease/imerslund-grasbeck-syndrome-type-2/
- https://rarediseases.info.nih.gov/diseases/7006/imerslund-grasbeck-syndrome
- https://www.oatext.com/Unusual-case-of-childhood-anemia-Imerslund-grasbeck-syndrome-a-case-report.php
- https://www.nature.com/articles/pr2011163
- https://karger.com/nef/article/23/6/297/212796/Selective-Vitamin-B12-Malabsorption-with
- https://pubmed.ncbi.nlm.nih.gov/13828999/
- https://jamanetwork.com/journals/jamapediatrics/fullarticle/505503
- https://en.wikipedia.org/wiki/Imerslund–Gräsbeck_syndrome
- https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.0954-6820.1960.tb03549.x
